Teva reveals delay in migraine timeline, reports earnings

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said in its 1Q18 earnings that it does not expect FDA to approve its BLA for migraine prophylactic

Read the full 254 word article

User Sign In